The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 62, Issue 5, 2005, Pages 1432-1437

  Schild, Steven E ^a   Wong, William W ^a   Vora, Sujay A ^a   Halyard, Michele Y ^a   Northfelt, Donald W ^a   Kogut, Heidi L ^a   Wheeler, Richard H ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cisplatin; Combined modality therapy; Hyperfractionated radiation therapy; Non small cell lung cancer; Three times a day RT

Indexed keywords

BIOLOGICAL ORGANS; CELLS; DOSIMETRY; ONCOLOGY; PULMONARY DISEASES; TOXICITY; TUMORS;

CONCURRENT DAILY CISPLATIN (CDDP); NON SMALL CELL LUNG CANCER; SYSTEMIC THERAPY;

RADIOTHERAPY;

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CONTRAST MEDIUM; PACLITAXEL;

ACUTE TOXICITY; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CARDIOTOXICITY; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CHRONIC TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MEGADOSE; DYSPHAGIA; ESOPHAGITIS; FATIGUE; FEMALE; GAMMA KNIFE RADIOSURGERY; HUMAN; HYPONATREMIA; LOBAR PNEUMONIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL TIME; TREATMENT FAILURE; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGITIS; HUMANS; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE; PILOT PROJECTS; PNEUMONIA; RADIOTHERAPY DOSAGE;

EID: 22144496750     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.01.003     Document Type: Article

References (18)

1. A. Jemal, R. Tiwari, T. Murray Cancer statistics, 2004 CA Cancer J Clin 54 2004 8 29
2. A. Perez-Carlos Nonsmall cell carcinoma of the lung Dose-time parameters Cancer Treatment Symposia 2 1985 131 142
3. Videtic G, Vokes E, Turrisi A, et al. The survival of patients treated for stage III non-small cell lung cancer in North America has increased during the past 25 years. Meeting Program for the 39th annual meeting of the American Society of Clinical Oncology, 2003, pg 291 (abstr 2557).
4. R.O. Dillman, J. Herndon, S.L. Seagren Improved survival in Stage III nonsmall cell lung cancer Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial J Natl Cancer Inst 88 1996 1210 1215
5. W.T. Sause, C. Scott, S. Taylor RTOG 8808 ECOG 4588 5-year results of a Phase III trial in regionally advanced unresectable non-small cell lung cancer [Abstract] Proc Am Soc Clin Oncol 17 1998 453a
6. T. LeChevalier, R. Arriagada, M. Tarayre Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma J Natl Cancer Inst 84 1992 58
7. Non-Small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer A meta-analysis using updated data on individual patients from 52 randomized clinical trials BMJ 311 1995 899 909
8. C. Schaake-Koning, W. Vanden Bogaert, O. Dalesio Effects of concomitant cisplatin and radiotherapy on inoperable nonsmall cell lung cancer N Engl J Med 326 1992 524 530
9. K. Furuse, M. Fukuoka, M. Kawahara Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer J Clin Oncol 17 1999 2692 2699
10. W. Curran, C. Scott, C. Langer Phase III comparison of sequential vs. concurrent chemo radiation for pts. with unresected stage III non-small cell lung cancer (NSCLC) Initial report of radiation therapy Oncology Group (RTOG) 94-10 [Abstract] J Clin Oncol 19 2000 484a
11. R. Komaki, W. Seiferheld, W. Curran Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC) Analysis of failures in a phase III study (RTOG 9410) [Abstract] Int J Radiat Oncol Biol Phys 48 2000 113
12. M. Saunders, S. Dische, A. Barrett Continuous hyperfractionated accelerated radiotherapy versus conventional radiotherapy in nonsmall cell lung cancer A randomized multicentre trial Lancet 350 1997 161 165
13. S.E. Schild, W.W. Wong, S.V. Vora Phase I study of hyperfractionated accelerated radiotherapy and escalating doses of daily cisplatin for patients with locally advanced non-small-cell lung cancer Int J Radiat Oncol Biol Phys 54 2002 729 734
14. S.E. Schild, P.J. Stella, S.M. Geyer Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small cell lung cancer (NSCLC) Int J Radiat Oncol Biol Phys 54 2002 370 378
15. P. Kirkbride, M. Hatton, P. Lorigan Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced non-small cell lung cancer Clin Oncol 14 2002 361 366
16. E.N. Oral, S. Bavbek, A. Kizir Preliminary analysis of a Phase II study of paclitaxel and continuous hyperfractionated accelerated radiotherapy in locally advanced non-small cell lung cancer Lung Cancer 25 1999 191 198
17. M.P. Mehta, S.P. Tannehill, S. Adak Phase II trial of hyperfractionated accelerated radiation therapy for unresectable non-small cell lung cancer, results of ECOG 4593 J Clin Oncol 16 1998 3518 3523
18. C. Belani, W. Wang, D. Johnson ECOG 2597 Phase III study of induction chemotherapy followed by standard thoracic radiotherapy (STD TRT) vs. hyperfractionated accelerated radiotherapy (HART) for patients with unresectable Stage III A & B non-small cell lung cancer [Abstract] Lung Cancer 41 2003 39